Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Nyxoah S.A. (NYXH.BR)

Brussels - Brussels Delayed Price. Currency in EUR
4.8200-0.3300 (-6.41%)
At close: 05:35PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.1500
Open5.0600
BidN/A x N/A
AskN/A x N/A
Day's Range4.7500 - 5.0600
52 Week Range4.7500 - 21.5000
Volume15,135
Avg. Volume3,910
Market Cap124.223M
Beta (5Y Monthly)0.94
PE Ratio (TTM)N/A
EPS (TTM)-0.6770
Earnings DateNov 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.50
  • GlobeNewswire

    Nyxoah to Participate in the Piper Sandler 34th Annual Healthcare Conference

    Nyxoah to Participate in the Piper Sandler 34th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – November 17, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which takes place November 2

  • Zacks

    Wall Street Analysts See a 240% Upside in Nyxoah SA (NYXH): Can the Stock Really Move This High?

    The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 240% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  • GlobeNewswire

    Nyxoah Reports Third Quarter 2022 Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Third Quarter 2022 Financial and Operating Results DREAM US pivotal 12-month clinical data expected in fall of 2023 Mont-Saint-Guibert, Belgium – November 8, 2022, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the quar

Advertisement
Advertisement